Schiavoni, G., Lucente, M., Di Folca, A., Alessandri, N., Mongiardo, R., and Manzoli, U
These modern medical treatments were developed to mimic this hormone and support better management of Type 2 diabetes
Injectable Wegovy begins at 0.25 mg once weekly for four weeks, then moves through additional four-week escalation stages before the usual maintenance dosage
Patients may be prescribed both medications when they have co-existing conditions requiring treatmentfor example, an individual with obesity who also requires smoking cessation support
The entire clinical development program, every pharmacokinetic study, every efficacy trial, every safety assessment, was conducted using subcutaneous injection